MRK : Summary for Merck & Company, Inc. Common St - Yahoo Finance

U.S. Markets open in 8 hrs 30 mins

Merck & Co., Inc. (MRK)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
60.33-0.84 (-1.37%)
At close: 4:01PM EST
People also watch
PFEJNJBMYLLYPG
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close61.17
Open61.05
Bid0.00 x
Ask0.00 x
Day's Range60.07 - 61.08
52 Week Range47.97 - 65.46
Volume11,397,928
Avg. Volume11,119,709
Market Cap166.34B
Beta0.83
PE Ratio (TTM)33.09
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.88 (3.06%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters6 hours ago

    Bristol-Myers won't seek accelerated Opdivo lung cancer approval

    Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for its combination of two immunotherapy drugs as an initial treatment for lung cancer. Bristol cited "a review of data available at this time" for the decision to hold off on filing for approval of the combination of its cancer drugs Opdivo and Yervoy. Merck last week said U.S. regulators had agreed to an accelerated review of its application to combine immune system-boosting drug Keytruda with chemotherapy as an initial therapy for advanced lung cancer.

  • Gilead, Merck, Alexion 2017 Views Hazy; Biogen May Surge: Analyst
    Investor's Business Daily8 hours ago

    Gilead, Merck, Alexion 2017 Views Hazy; Biogen May Surge: Analyst

    Barclays analyst Geoff Meacham on Thursday said he expected Gilead Sciences' 2017 outlook to be hindered on limited hepatitis C sales.

  • Merck, Biogen, Lilly Top 2016 Drug Approvals Despite FDA Slump
    Investor's Business Daily8 hours ago

    Merck, Biogen, Lilly Top 2016 Drug Approvals Despite FDA Slump

    The FDA's approval rate fell to a nine-year low in 2016 despite additions from Biogen, Merck and Eli Lilly.